Vertex Pharmaceuticals Stock Fair Value – VERTEX PHARMACEUTICALS Reports 6.4% Increase in Total Revenue for FY2023 Q3
November 23, 2023
☀️Earnings Overview
Vertex Pharmaceuticals ($NASDAQ:VRTX) reported their financial results for the third quarter of fiscal year 2023 on November 6, 2023. Total revenue amounted to USD 2483.5 million, a 6.4% increase from the same quarter of the previous year. Net income also rose 11.3% to USD 1035.3 million.
Analysis – Vertex Pharmaceuticals Stock Fair Value
GoodWhale has conducted an analysis of VERTEX PHARMACEUTICALS‘s wellbeing and determined that its intrinsic value stock is around $312.2. This figure was determined using GoodWhale’s proprietary Valuation Line. Currently, VERTEX PHARMACEUTICALS’s stock is being traded at $385.8, which is overvalued by 23.6%. This means that investors should be aware of the risks associated with investing in VERTEX PHARMACEUTICALS at its current price. Despite this overvaluation, if the stock continues to perform well then investors may still choose to invest in it. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Vertex Pharmaceuticals. More…
| Total Revenues | Net Income | Net Margin |
| 9.65k | 3.47k | 40.4% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Vertex Pharmaceuticals. More…
| Operations | Investing | Financing |
| 4.38k | -2.08k | -402.2 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Vertex Pharmaceuticals. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 21.73k | 5.21k | 64.08 |
Key Ratios Snapshot
Some of the financial key ratios for Vertex Pharmaceuticals are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 17.2% | 18.1% | 45.1% |
| FCF Margin | ROE | ROA |
| 43.6% | 17.0% | 12.5% |
Peers
The competition in the pharmaceutical industry is intense, with companies vying for market share in a constantly changing landscape. Vertex Pharmaceuticals Inc is no stranger to this competition, and its competitors include Nyrada Inc, Incyte Corp, and Gain Therapeutics Inc.
– Nyrada Inc ($ASX:NYR)
Nyrada Inc is a clinical stage biopharmaceutical company focused on the development of novel therapeutics to treat diseases of the eye, central nervous system and other organ systems. The company’s lead product candidate, NYX-2925, is a small molecule that inhibits the activity of the protein kinase C-beta (PKC-beta) enzyme. NYX-2925 is in clinical development for the treatment of dry eye disease and age-related macular degeneration.
Nyrada’s market cap is $21.06 million and its ROE is -20.85%. The company is focused on the development of novel therapeutics to treat diseases of the eye, central nervous system and other organ systems.
– Incyte Corp ($NASDAQ:INCY)
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company that focuses on the discovery, development, and commercialization of proprietary small molecule drugs to treat serious unmet medical needs, primarily in oncology.
As of 2022, Incyte Corporation had a market capitalization of $15.48 billion and a return on equity of 9.54%. The company’s main product is Jakafi (ruxolitinib), which is approved for the treatment of myelofibrosis and polycythemia vera, two rare blood disorders. Incyte is also developing several other drugs in clinical trials for various cancers.
– Gain Therapeutics Inc ($NASDAQ:GANX)
Gain Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of precision medicines for patients with serious diseases. The company’s lead product candidate is GT-004, a small molecule inhibitor of the oncogene c-Myc, which is in development for the treatment of solid tumors. Gain Therapeutics has a market cap of $36.13 million and a negative return on equity of 33.26%. The company’s products are still in development and have not yet been approved for sale by the FDA.
Summary
Vertex Pharmaceuticals reported strong third-quarter earnings for FY2023 with 6.4% growth in total revenue and 11.3% increase in net income. This is a positive indication of the company’s increasing financial health, which may be attractive to potential investors. With the company’s diverse portfolio of products and growing pipeline of new treatments, Vertex Pharmaceuticals has potential for further growth and could be a lucrative investing option. Investors should consider the company’s past performance, future potential, and risk factors before making any decisions.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
